+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Fibrotic Diseases Treatment Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 160 Pages
  • April 2024
  • Region: Global
  • Expert Market Research
  • ID: 5960383
The fibrotic diseases treatment market size is projected to grow at a compound annual growth rate (CAGR) of 7.8%, during a forecast period of 2024 to 2032. The major factors driving the market growth are the increasing prevalence of fibrotic diseases, the rising awareness and diagnosis of these conditions, the development of novel therapies and biomarkers, and the unmet medical needs in this field.

Fibrotic diseases are chronic and progressive conditions that result from the excessive deposition of scar tissue in various organs, such as the lungs, liver, kidneys, and skin. Fibrosis can impair the normal function of the affected organs and lead to serious complications, such as respiratory failure, portal hypertension, renal failure, and skin ulcers.

Fibrotic Diseases Treatment Market Drivers and Constraints

The key drivers of the fibrotic disease treatment market are:

  • The increasing prevalence of fibrotic diseases, especially idiopathic pulmonary fibrosis (IPF), which affects about 3 million people worldwide and has a high mortality rate of 50% within 3 to 5 years of diagnosis. The incidence of IPF is expected to increase with the aging population and the exposure to environmental and occupational risk factors, such as smoking, air pollution, and viral infections.
  • The rising awareness and diagnosis of fibrotic diseases, due to the availability of improved diagnostic tools, such as high-resolution computed tomography (HRCT), lung function tests, and biomarkers, as well as the efforts of various organizations, such as the Pulmonary Fibrosis Foundation, the European IPF Network, and the Global IPF Initiative, to raise awareness and provide education and support to patients and caregivers.
  • The development of novel therapies and biomarkers, which aim to target the underlying mechanisms of fibrosis, such as inflammation, oxidative stress, fibroblast activation, and extracellular matrix remodeling. Some of the promising therapies in the pipeline include anti-fibrotic agents, such as pirfenidone and nintedanib, which are approved for IPF; anti-inflammatory agents, such as pamrevlumab and GLPG1690, which are in phase 3 trials for IPF; and gene therapies, such as GFB-301 and QR-1123, which are in preclinical and phase 1/2 trials for IPF. Moreover, several biomarkers, such as KL-6, MMP-7, and galectin-3, are being explored for the diagnosis, prognosis, and monitoring of fibrotic diseases.
  • The unmet medical needs in the fibrotic diseases treatment market, as there is no cure for most of these conditions and the current therapies are limited by their efficacy, safety, and accessibility. There is a high demand for more effective, safer, and affordable treatments that can halt or reverse the progression of fibrosis, improve the quality of life and survival of patients, and reduce the burden on the healthcare system.

The key constraints of the fibrotic diseases treatment market are:

  • The lack of a clear understanding of the etiology and pathophysiology of fibrotic diseases, which hampers the identification of novel targets and the development of specific and personalized therapies. Fibrosis is a complex and heterogeneous process that involves multiple factors, such as genetics, epigenetics, environment, and immunity, and varies across different organs and diseases. Therefore, there is a need for more research and collaboration to elucidate the molecular and cellular mechanisms of fibrosis and to identify the common and unique pathways and biomarkers that can be modulated by therapeutic interventions.
  • The high cost and low accessibility of the existing therapies, especially in the developing and emerging markets, where the prevalence of fibrotic diseases is high but the awareness and diagnosis are low. The current therapies, such as pirfenidone and nintedanib, are expensive and require frequent monitoring and dose adjustment, which limits their affordability and availability for many patients. Moreover, there are significant disparities in the reimbursement and regulatory policies across different regions and countries, which affect the access and adoption of these therapies.
  • The challenges in the clinical development and approval of new therapies, due to the lack of standardized and validated endpoints, biomarkers, and animal models for fibrotic diseases. The current endpoints, such as forced vital capacity (FVC) and mortality, are not sensitive and specific enough to capture the clinical benefit and the disease progression of fibrotic diseases. Moreover, the existing biomarkers and animal models are not fully representative of the human fibrotic conditions and do not correlate well with the clinical outcomes. Therefore, there is a need for more robust and reliable endpoints, biomarkers, and animal models that can facilitate the design and execution of clinical trials and the evaluation and approval of new therapies.

Fibrotic Diseases Treatment Market Trends and Developments

The treatment market for fibrotic diseases, which include conditions like idiopathic pulmonary fibrosis, liver fibrosis, and kidney fibrosis, is witnessing several emerging trends and developments:

Targeted Therapies: There is a growing focus on developing targeted therapies that specifically address the underlying mechanisms of fibrosis, such as the inhibition of transforming growth factor-beta (TGF-β) and connective tissue growth factor (CTGF). These therapies aim to halt or reverse the fibrotic process.

  • Antifibrotic Agents: The use of antifibrotic agents, such as pirfenidone and nintedanib, has become more prevalent in treating idiopathic pulmonary fibrosis. These drugs have shown promise in slowing the progression of fibrosis and improving patient outcomes.
  • Combination Therapies: Researchers are exploring the potential of combination therapies that use different mechanisms of action to target multiple pathways involved in fibrotic diseases. This approach aims to enhance the efficacy of treatment and address the complexity of fibrotic diseases.
  • Personalized Medicine: There is an increasing interest in personalized medicine approaches that tailor treatment to individual patient characteristics, such as genetic makeup and biomarker profiles. This approach seeks to optimize treatment efficacy and minimize adverse effects.
  • Regenerative Medicine: Advances in regenerative medicine, including cell-based therapies and tissue engineering, offer potential new avenues for treating fibrotic diseases by promoting tissue repair and regeneration.
  • Clinical Trials: The number of clinical trials investigating novel therapeutic agents and combinations for fibrotic diseases is growing, reflecting the active research and development efforts in this area.
  • Market Expansion: The global market for fibrotic disease treatments is expected to expand due to the increasing prevalence of fibrotic conditions, rising awareness, and the introduction of new therapies.
  • Collaborations and Partnerships: Pharmaceutical companies and research institutions are increasingly collaborating and forming partnerships to accelerate the development and commercialization of new treatments for fibrotic diseases.
These trends and developments indicate a dynamic and evolving landscape in the treatment market for fibrotic diseases, with ongoing research and innovation aimed at improving patient outcomes and quality of life.

Fibrotic Diseases Treatment Market Segmentation

The fibrotic diseases treatment market can be segmented by treatment type, application, end user, and region.

Market Breakup by Treatment Type

  • Medication
  • Organ Transplantation
  • Oxygen Therapy
  • Others

Market Breakup by Applications

  • Idiopathic Pulmonary Fibrosis
  • Hepatic Cirrhosis
  • Renal Fibrosis
  • Cutaneous Fibrosis
  • Others

Market Breakup by End User

  • Hospitals
  • Academic and Research Institutes
  • Others

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • China

Fibrotic Diseases Treatment Market: Competitive Landscape

The competitive landscape of the fibrotic diseases treatment market is characterized by the presence of several key players, such Genentech, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc., Bristol-Myers Squibb Company, BellBrook Labs, Enveda Biosciences, Gilead Sciences, Inc., KITHER BIOTECH S.R.L., Verona Pharma plc, Alpine Immune Sciences, Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH and Accord Healthcare.

These players are involved in various strategies, such as product development and innovation, clinical trials and research, licensing and collaboration, mergers and acquisitions, and market expansion and penetration, to gain a competitive edge and capture a larger market share.


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Fibrotic Diseases Treatment Market Overview - 8 Major Markets
3.1 Fibrotic Diseases Treatment Market Historical Value (2017-2023)
3.2 Fibrotic Diseases Treatment Market Forecast Value (2024-2032)
4 Fibrotic Diseases Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Fibrotic Diseases Epidemiology Scenario and Forecast - 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.5 India Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
7 Fibrotic Diseases Treatment Market Landscape - 8 Major Markets
7.1 Fibrotic Diseases Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Fibrotic Diseases Treatment: Product Landscape
7.2.1 Analysis by Treatment
7.2.2 Analysis by Applications
8 Fibrotic Diseases Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Fibrotic Diseases Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Fibrotic Diseases Treatment Market Segmentation (2017-2032) - 8 Major Markets
11.1 Fibrotic Diseases Treatment Market (2017-2032) by Treatment Type
11.1.1 Market Overview
11.1.2 Medication
11.1.3 Organ Transplantation
11.1.4 Oxygen Therapy
11.1.5 Others
11.2 Fibrotic Diseases Treatment Market (2017-2032) by Applications
11.2.1 Market Overview
11.2.2 Idiopathic Pulmonary Fibrosis
11.2.3 Hepatic Cirrhosis
11.2.4 Renal Fibrosis
11.2.5 Cutaneous Fibrosis
11.2.6 Others
11.3 Fibrotic Diseases Treatment Market (2017-2032) by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Academic and research institutes
11.3.4 Others
11.4 Fibrotic Diseases Treatment Market (2017-2032) by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
11.4.5 India
12 United States Fibrotic Diseases Treatment Market (2017-2032)
12.1 United States Fibrotic Diseases Treatment Market Historical Value (2017-2023)
12.2 United States Fibrotic Diseases Treatment Market Forecast Value (2024-2032)
12.3 United States Fibrotic Diseases Treatment Market (2017-2032) by Treatment Type
12.3.1 Market Overview
12.3.2 Medication
12.3.3 Organ Transplantation
12.3.4 Oxygen Therapy
12.3.5 Others
12.4 United States Fibrotic Diseases Treatment Market (2017-2032) by Applications
12.4.1 Market Overview
12.4.2 Idiopathic pulmonary fibrosis
12.4.3 Hepatic cirrhosis
12.4.4 Renal fibrosis
12.4.5 Cutaneous fibrosis
12.4.6 Others
13 EU-4 and United Kingdom Fibrotic Diseases Treatment Market (2017-2032)
13.1 EU-4 and United Kingdom Fibrotic Diseases Treatment Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Fibrotic Diseases Treatment Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Fibrotic Diseases Treatment Market (2017-2032) by Treatment Type
13.3.1 Market Overview
13.3.2 Medication
13.3.3 Organ Transplantation
13.3.4 Oxygen Therapy
13.3.5 Others
13.4 EU-4 and United Kingdom Fibrotic Diseases Treatment Market (2017-2032) by Applications
13.4.1 Market Overview
13.4.2 Idiopathic pulmonary fibrosis
13.4.3 Hepatic cirrhosis
13.4.4 Renal fibrosis
13.4.5 Cutaneous fibrosis
13.4.6 Others
14 Japan Fibrotic Diseases Treatment Market
14.1 Japan Fibrotic Diseases Treatment Market Historical Value (2017-2023)
14.2 Japan Fibrotic Diseases Treatment Market Forecast Value (2024-2032)
14.3 Japan Fibrotic Diseases Treatment Market (2017-2032) by Treatment Type
14.3.1 Market Overview
14.3.2 Medication
14.3.3 Organ Transplantation
14.3.4 Oxygen Therapy
14.3.5 Others
14.4 Japan Fibrotic Diseases Treatment Market (2017-2032) by Applications
14.4.1 Market Overview
14.4.2 Idiopathic pulmonary fibrosis
14.4.3 Hepatic cirrhosis
14.4.4 Renal fibrosis
14.4.5 Cutaneous fibrosis
14.4.6 Others
15 India Fibrotic Diseases Treatment Market
15.1 India Fibrotic Diseases Treatment Market (2017-2032) Historical Value (2017-2023)
15.2 India Fibrotic Diseases Treatment Market (2017-2032) Forecast Value (2024-2032)
15.3 India Fibrotic Diseases Treatment Market (2017-2032) by Treatment Type
15.3.1 Market Overview
15.3.2 Medication
15.3.3 Organ Transplantation
15.3.4 Oxygen Therapy
15.3.5 Others
15.4 India Fibrotic Diseases Treatment Market (2017-2032) by Applications
15.4.1 Market Overview
15.4.2 Idiopathic pulmonary fibrosis
15.4.3 Hepatic cirrhosis
15.4.4 Renal fibrosis
15.4.5 Cutaneous fibrosis
15.4.6 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Genentech, Inc.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Boehringer Ingelheim International GmbH
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 AbbVie Inc.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Bristol-Myers Squibb Company
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 BellBrook Labs
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Enveda Biosciences
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Gilead Sciences, Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 KITHER BIOTECH S.R.L.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Verona Pharma plc
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Alpine Immune Sciences
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Intercept Pharmaceuticals, Inc.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 Teva Pharmaceutical Industries Ltd.
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 Sandoz International GmbH
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
22.14 Accord Healthcare
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisitions
22.14.5 Certifications
List not exhaustive
23 Fibrotic Diseases Treatment Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The research team strives to make this section as comprehensive as possible.

Companies Mentioned

  • Genentech Inc.
  • Boehringer Ingelheim International GmbH
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • BellBrook Labs
  • Enveda Biosciences
  • Gilead Sciences Inc.
  • KITHER BIOTECH S.R.L.
  • Verona Pharma plc
  • Alpine Immune Sciences
  • Intercept Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Accord Healthcare

Methodology

Loading
LOADING...